Blocking the IGF1 receptor with picropodophyllin alleviated both baseline hypersensitivity and acute pain attacks in a chronic migraine mouse model, while reducing CGRP and c-Fos expression — identifying IGF1/IGF1r signaling as a new therapeutic target.
Reduced CGRP + pain behaviorsIGF1r antagonist PPP alleviated both baseline hypersensitivity and acute allodynia while reducing CGRP expression in the trigeminal nucleus — an upstream target for migraine
What the researchers found
IGF1r antagonist picropodophyllin alleviated chronic migraine-related pain behaviors and reduced CGRP and c-Fos expression in the trigeminal nucleus caudalis, identifying IGF1/IGF1r signaling as a contributor to chronic migraine.
Why it matters
Despite anti-CGRP drugs improving migraine treatment, many patients don't respond adequately. IGF1/IGF1r represents an upstream pathway that drives CGRP expression and neuronal sensitization. Targeting this pathway could help patients who don't respond to CGRP-based therapies, offering a complementary or alternative approach to chronic migraine prevention.
The numbers in context
NTG-induced chronic migraine model; IGF1/IGF1r pathway targeted; pain relief and autophagy restoration demonstrated.
How the study worked
Chronic migraine induced in mice by repeated nitroglycerin (NTG) injections. Assessed mechanical and thermal sensitivity. Treated with IGF1r antagonist PPP. Measured IGF1, phospho-IGF1r, CGRP, c-Fos expression, and autophagy markers in the TNC by immunostaining and Western blot.
Who was studied
Mice with NTG-induced chronic migraine model
What this study cannot tell us
Mouse model using nitroglycerin injections — an imperfect model of human chronic migraine. PPP is a research tool compound, not an approved drug. The specific mechanism linking IGF1r signaling to CGRP upregulation wasn't fully delineated. Only mechanical and thermal sensitivity were assessed — migraine involves many other symptoms. No human data.
How to read the evidence
Preliminary — single animal study using a nitroglycerin-induced chronic migraine model. Demonstrates mechanism but no human validation or clinical data.
When this study was published
Published in 2024, contributing to the expanding understanding of molecular pathways beyond CGRP in chronic migraine.
The bigger picture
Anti-CGRP therapies have been the biggest advance in migraine treatment in decades, but they don't work for everyone. This study identifies IGF1/IGF1r as an upstream regulator of CGRP in chronic migraine, potentially explaining a mechanism driving CGRP overproduction. If IGF1r blockade can reduce CGRP levels at their source, it could provide relief for patients who don't respond to anti-CGRP drugs, and the combination might be even more effective.
Questions still open
- Would IGF1r inhibitors work in chronic migraine patients who don't respond to anti-CGRP therapies?
- Is the IGF1/IGF1r pathway specifically activated in human chronic migraine, or is this an artifact of the mouse model?
- Could combining IGF1r blockade with anti-CGRP therapy provide superior migraine prevention?
Common questions
What does IGF1 have to do with migraines?
Could this lead to new migraine treatments?
Read the original research
Targeting IGF1/IGF1r signaling relieve pain and autophagic dysfunction in NTG-induced chronic migraine model of mice.
The journal of headache and pain, 25(1), 156
Citation
Wang, Tianxiao; Zhu, Chenlu; Zhang, Kaibo; Gao, Jinggui; Xu, Yunhao; Duan, Chenyang; Wu, Shouyi; Peng, Cheng; Guan, Jisong; Wang, Yonggang. (2024). Targeting IGF1/IGF1r signaling relieve pain and autophagic dysfunction in NTG-induced chronic migraine model of mice.. The journal of headache and pain, 25(1), 156. https://doi.org/10.1186/s10194-024-01864-6